4DMedical

4DMedical progresses to a commercial agreement with Qscan

Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces the signing of a commercial contract with Qscan Radiology Clinics ("Qscan"), a leading provider of diagnostic imaging services in Queensland. This agreement follows a successful pilot of 4DMedical’s products with Qscan, and represents the first Australian contract to incorporate products from both the Pulmonary Function and Pulmonary Structure suites, including CT LVAS™.


Pilot success leads to commercial agreement

With 40 clinics across Queensland, New South Wales, ACT, Tasmania, and Western Australia, Qscan is one of Australia’s leading medical imaging providers, offering a comprehensive range of diagnostic and interventional radiology services.

Following the success of a pilot program, which demonstrated the clinical and operational effectiveness of 4DMedical’s proprietary suite of products, 4DMedical and Qscan have entered a commercial arrangement under which Qscan will offer 4DMedical’s respiratory imaging solutions at select practices in Brisbane.

This agreement marks 4DMedical’s first Australian commercial contract to incorporate products from both its Pulmonary Function and Pulmonary Structure suites. Specifically, the agreement with Qscan will provide clinicians with access to CT LVAS™, Lung Density Analysis™ - Inspiration (LDAi), Functional Lung Density Analysis™ (LDAf), and Lung Texture Analysis™ (LTA), each providing advanced diagnostic capabilities to support referrers and patients.

Reports will be delivered and billed on a Software-as-a-Service model on terms in line with those of the Company’s other commercial partners.

4DMedical MD/CEO and Founder Andreas Fouras said:

Having completed our pilot with Qscan, we are excited to have progressed to a commercial agreement. This partnership ensures that more patients and clinicians have access to detailed, actionable insights into lung health, supporting better healthcare outcomes.

Momentum continues to build with the commercialisation of our technology across the US and Australia. With the addition of Qscan to our network of providers in Australia, I am excited to see our footprint expand to ensure our cutting-edge technology is now becoming more readily available to all Australians.


Click here for the full ASX Release

This article includes content from 4DMedical, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Rocketboots Limited

Appendix 4D & Half Year Report (1H25)

Artificial Intelligence software companyRocketBoots Limited (ASX:ROC) (RocketBoots or the Company) has announced Appendix 4D & Half Year Report (1H25).


Keep reading...Show less
Nanoveu

Binding Share Sale Agreement Executed with EMASS

Nanoveu positioned to accelerate growth in AI-driven edge semiconductor solutions

Nanoveu Limited ("Nanoveu" or the "Company") (ASX: NVU), following on from its announcements on 15 October 2024 and 22 November 2024, is pleased to announce the completion of its binding Share Sale Agreement regarding its 100% acquisition of Embedded A.I. Systems Pte. Ltd. (“EMASS”), a leading System-on-Chip (SoC) semiconductor design company, following shareholder approval and completion of due diligence4. This transaction marks a key strategic moment for Nanoveu and adds cutting edge semiconductor technology to its suite of commercial offerings.

Keep reading...Show less
BlinkLab

North Shore Pediatric Therapy in Chicago Joins BlinkLab’s US Registrational Study

BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”), an innovative digital healthcare company developing AI-powered smartphone technology to transform the autism and ADHD diagnostic markets, is pleased to announce that North Shore Pediatric Therapy (“NSPT”) is joining our US clinical study. NSPT is the second US-based site to on-board for the 100-patient initial phase of the registrational study. Enrolment from the NSPT-site is expected to commence in the coming weeks.

Keep reading...Show less
Bar chart.

Tech 5: AMD, Alphabet, Amazon and More Report Results as Big Tech Earnings Roll Out

Trade tensions dominated the macroeconomic landscape this week, impacting the tech sector.

US President Donald Trump's confirmation of tariffs against Canada and Mexico resulted in significant market losses on Monday (February 3) before negotiations led to temporary delays in their implementation.

Uncertainties are ongoing, but investors remained resilient, seizing opportunities in the face of volatility as Big Tech earnings reports drove fluctuations in the Nasdaq Composite (INDEXNASDAQ:.IXIC) and S&P 500 (INDEXSP:.INX).

Keep reading...Show less
ChatGPT logo overlayed on human profile.

How to Invest in OpenAI's ChatGPT

OpenAI’s ChatGPT is one of the latest technological breakthroughs in the artificial intelligence space. But what is ChatGPT, and can you invest in OpenAI?

This emerging technology is representative of a niche subsector of the AI industry known as generative AI — systems that can generate text, images or sounds in response to prompts given by users.

Precedence Research expects the global AI market to grow at a compound annual growth rate (CAGR) of 19.1 percent to reach US$3.68 trillion by 2034. Just how much of an impact OpenAI’s ChatGPT will have on this space is hard to predict, but Fortune Business Insights estimates that the total market revenue of generative AI will see a CAGR of 39.6 percent through 2032, increasing from US$67.18 billion last year to US$967.65 billion in 2032.

Keep reading...Show less

Latest Press Releases

Related News

×